[Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity]

Vopr Onkol. 2010;56(5):597-602.
[Article in Russian]

Abstract

Two modalities of chemoradiotherapy for locally advanced squamous cell cancer of oro-hypopharynx and oral cavity were compared in the treatment of 34 patients. Five-year survival after cisplatin, 5-FU, taxotere, and carboplatin plus irradiation with TTD of 68-72 Gy (group 1) was 59.5% versus 13.8% without taxotere (group 2). Relapse was in 9 cases (60%) (4 - group 1 and 5 - group 2). Post-therapeutic complication stage III-IV was 57.8% (group 1) and 48% (group 2).

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy
  • Chemotherapy, Adjuvant / adverse effects
  • Docetaxel
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Glottis*
  • Humans
  • Kaplan-Meier Estimate
  • Laryngeal Neoplasms / drug therapy*
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Mouth Neoplasms / drug therapy*
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / radiotherapy
  • Neoplasm Staging
  • Platinum Compounds / administration & dosage
  • Radiotherapy, Adjuvant / adverse effects
  • Taxoids / adverse effects
  • Taxoids / therapeutic use*
  • Treatment Outcome

Substances

  • Platinum Compounds
  • Taxoids
  • Docetaxel
  • Fluorouracil